论文部分内容阅读
目的:探讨骨肉瘤组织中肝细胞生长因子受体c-met蛋白的表达情况,分析其临床意义及与预后的关系。方法:应用免疫组织化学方法检测行手术的35例骨肉瘤及13例骨样骨瘤患者标本肝细胞生长因子受体c-met的表达,并分析其与临床因素和预后的关系。结果:骨肉瘤组织中肝细胞生长因子受体c-met的阳性表达率为80%(28/35),而在骨样骨瘤中的表达率为7.7%(1/12),两者比较显著差异(P<0.01);结合临床资料分析,其表达与患者性别、年龄、发病次数、肿瘤体积、病理分型无关(P>0.05),而与临床分期、有无转移有关(P<0.05)。结论:C-met可能在骨肉瘤细胞侵袭、转移的过程中起重要作用;肝细胞生长因子受体c-met可以作为骨肉瘤诊断和预测转移的指标。
Objective: To investigate the expression of hepatocyte growth factor receptor c-met protein in osteosarcoma and to analyze its clinical significance and prognosis. Methods: Immunohistochemistry was used to detect the expression of c-met of hepatocyte growth factor receptor in 35 cases of osteosarcoma and 13 cases of osteosarcoma. The relationship between them and clinical factors and prognosis was analyzed. Results: The positive rate of c-met expression in osteosarcoma was 80% (28/35), while it was 7.7% (1/12) in osteoid osteoma (P <0.05), but not with clinical stage, metastasis (P <0.05). There was no correlation between clinical stage and metastasis ). CONCLUSION: C-met may play an important role in the invasion and metastasis of osteosarcoma cells. The hepatocyte growth factor receptor c-met can be used as a marker for the diagnosis and prognosis of osteosarcoma.